Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Thomas Cheung Yau"'
Autor:
Anthony J. Good, Mark T. Marino, Nicholas J. Ede, Leslie Chong, Christoph C. Zielinski, Joshua Tobias, Mirjana Drinic, Teerapat Ungtrakul, Wen-Chi Chou, Li-Yuan Bai, Aumkhae Sookprasert, Jedzada Maneechavakajorn, Suebpong Tanasanvimon, Thomas Cheung Yau, Chia-Jui Yen, Chaiyut Charoentum, Wichit Arpornwirat, Arunee Dechaphunkul, Iurie Bulat, Marina Maglakelidze, Yee Chao, Erika Garner-Spitzer, Ursula Wiedermann
Supplementary Data 3 & 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaf4da22beef67401032aee58a6e5653
https://doi.org/10.1158/1078-0432.22480941
https://doi.org/10.1158/1078-0432.22480941
Autor:
Anthony J. Good, Mark T. Marino, Nicholas J. Ede, Leslie Chong, Christoph C. Zielinski, Joshua Tobias, Mirjana Drinic, Teerapat Ungtrakul, Wen-Chi Chou, Li-Yuan Bai, Aumkhae Sookprasert, Jedzada Maneechavakajorn, Suebpong Tanasanvimon, Thomas Cheung Yau, Chia-Jui Yen, Chaiyut Charoentum, Wichit Arpornwirat, Arunee Dechaphunkul, Iurie Bulat, Marina Maglakelidze, Yee Chao, Erika Garner-Spitzer, Ursula Wiedermann
Purpose:HER2/neu is overexpressed in up to 30% of gastroesophageal adenocarcinomas (GEA) and linked to poor prognosis. Recombinant mAbs to treat HER2/neu-overexpressing cancers are effective with limitations, including resistance and toxicity. Theref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f60e21e29115932209d40d9524bea17
https://doi.org/10.1158/1078-0432.c.6530562.v1
https://doi.org/10.1158/1078-0432.c.6530562.v1
Autor:
Anthony J. Good, Mark T. Marino, Nicholas J. Ede, Leslie Chong, Christoph C. Zielinski, Joshua Tobias, Mirjana Drinic, Teerapat Ungtrakul, Wen-Chi Chou, Li-Yuan Bai, Aumkhae Sookprasert, Jedzada Maneechavakajorn, Suebpong Tanasanvimon, Thomas Cheung Yau, Chia-Jui Yen, Chaiyut Charoentum, Wichit Arpornwirat, Arunee Dechaphunkul, Iurie Bulat, Marina Maglakelidze, Yee Chao, Erika Garner-Spitzer, Ursula Wiedermann
Supp. Table 1; Supp. Table 2; Supp. Table 3 A,B; Supp. Table 4; Supp. Table 5; Supp. Table 6; Supplementary Data 1; Supplementary Data 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f4b207604681307f928821deb571f02
https://doi.org/10.1158/1078-0432.22480935.v1
https://doi.org/10.1158/1078-0432.22480935.v1
Autor:
Winnie Yeo, Jeffrey Anderson, Thomas Cheung Yau, Tim Meyer, Ignacio Melero, Su Pin Choo, Chiun Hsu, Hao Tang, Bruno Sangro, Akhil Chopra, Jörg Trojan, Tae-You Kim, Christine Dela Cruz, Lixin Lang, Anthony B. El-Khoueiry, Masatoshi Kudo, Jaclyn Neely, Todd S. Crocenzi, Theodore H. Welling
Publikováno v:
Journal of Clinical Oncology. 35:226-226
226 Background: HCC diagnosed at advanced stages has a poor prognosis. Patients who progress on sorafenib have few options. Nivolumab, a fully human IgG4 monoclonal antibody inhibitor of programmed death-1 (PD-1), has demonstrated clinical and surviv